{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 3', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 3', 'Amendment date:', '19 October 2018', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'Removal of all STGG (Skim Milk-Tryptone-Glucose-Glycerol) wording', 'throughout the protocol. STGG product not being available, it has been decided', 'to replace it with cryobeads for storage of bacterial isolates. PCR testing on', 'samples stored in cryobeads was shown to be as efficient as for samples stored in', 'STGG. Besides, this decision has been taken for alignment with other COPD', 'studies, where STGG solutions are no longer used.', 'Clarification of technique used for target identification. For the primary endpoint,', 'various viral pathogens will be identified but not quantified. Along this line, the', 'wording \"and by HRV quantitative RT-PCR\" has been removed from primary', 'endpoint to avoid confusion as HRV viral load data will be reported as part of the', 'tertiary endpoints.', 'Clarification in exclusion criteria section (4.3). Administration of antibiotics', 'before study entry, where study entry is meant to be Visit 1.', 'Clarification in study procedure section (6.3) and in the section for recording', 'current medication (6.4.2.10) during scheduled visits, where it has been specified', 'that recording of any current medication is applicable for any disease not only', 'COPD-related. Moreover, a footnote referring to Table 10 \"Reporting period for', 'SAE and AEs leading to withdrawal\" has been added for further clarification,', 'both in Table 4 and 5.', 'Addition of a section (actual 6.4.2.6) for Pregnancy test for Visit 1, Visit 2 and', 'Visit 3. A Pregnancy test section for Screening Visit was included during', 'Protocol Amendment 1: to be consistent, same wording has been included for the', 'subsequent visits.', '19-OCT-2018', '113', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Clarification of reporting of severe AECOPDs. Two sentences have been added', 'in sections 7.1.1 and 7.2.2.1 for making clear that severe AECOPD events are not', 'to be reported as SAE as they are meant as disease-related outcomes.', 'Rewording in the table concerning reporting period for SAE and AEs leading to', 'withdrawal for better clarification (Table 10).', 'Addition of a new outsourced laboratory (DDL).', 'To correct some typographical errors.', 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'List of Abbreviations', 'STGG', 'Skim Milk Tryptone Glucose Glycerol', 'Section 4.3 Exclusion criteria for enrolment', 'Administration of antibiotics within 1 month of study entry OR continuous', 'administration of antibiotics (defined as more than 30 days in total) within 90 days', 'before study entry.', '* Study entry is Visit 1. If this exclusion criteria is met during Screening Visit the', 'patient can enter the study and this exclusion criteria will be reassessed during Visit', '1.', '19-OCT-2018', '114', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.3 Outline of study procedures', 'Table 4 List of study procedures for scheduled visits', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Informed consenta', 'Check inclusion/exclusion criteriaa', 'O', 'Record demographic data', 'Record medical history', 'Record history of AECOPD within the previous yearb', 'Record intercurrent comorbidities', 'O', 'Record history of pneumococcal and influenza', 'O', 'vaccination', 'Smoking exposure history (ATS-DLD-78A questionnaire)/', 'biomass exposure history (Biomass Exposure', 'O', 'questionnaire)', 'Smoking status', 'Physical examination including vital signsh', 'O', 'O', 'O', 'Urine Pregnancy Test', 'Measure/ record height and weightd', 'Pre- and post-bronchodilator spirometrye', 'Chest X-rayf', \"Record subject's COPD status (stable, recovered or not\", 'recovered)', 'Record current medication for COPD', 'Record healthcare resource utilisation', 'Record additional treatments prescribed by primary and', 'secondary care physicians', 'Train subject on use of electronic Diary Card and assign', 'O', 'O', 'electronic Diary Card to the subject', 'Return electronic Diary Card', 'O', 'Sputum samplingg', 'Blood samples for biomarkers', 'Record Adverse Events (AEs)* related to stud', 'participation', 'Record serious adverse events (SAEs)^ related to study', 'participation', 'Screening conclusion', 'Study conclusion', 'HRQOL questionnaires:', 'CAT', 'O', 'O', 'O', 'SGRQ-C', 'O', 'O', 'O', 'A Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'h Physical examination (Visit1-3) should be done only if necessary by the investigator or delegate.', '19-OCT-2018', '115', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}